# CHRONO | Metabolic Cancer Fingerprint
**Submission for Gemma 4 Good Hackathon 2026**

## 1. Problem: The Diagnostic Blind Spot
Routine blood tests are the most common medical procedure worldwide. However, they are currently analyzed using population-level reference ranges (the 2.5th–97.5th percentile of millions of strangers). This creates a "blind spot": a patient's markers can fluctuate dramatically within the "normal" range while signaling early-stage malignancy, but these signals are ignored until they cross a population threshold—often when the cancer is already Stage 3 or 4.

## 2. Solution: The Trident Signal System
CHRONO is an AI-driven metabolic anomaly detection system that identifies pre-cancerous fingerprints 3–5 years before structural symptoms appear. 

### Core Innovation: Personal Baselines
Instead of population ranges, CHRONO computes each patient's own biological setpoint (mean ± 1.5 SD) from their unique history. We track the **Trident Signal**:
- **Warburg Index Velocity (WIV):** Rate of shift toward aerobic glycolysis (LDH/RDW/Glucose).
- **Biological Age Velocity (BAV):** Cellular aging acceleration (PhenoAge algorithm).
- **Immune Collapse Velocity (ICV):** Inflammatory ratio deterioration (NLR/PLR/RAR).

## 3. Gemma 4 Implementation

### Layer 1: Document Vision & Audio (Gemma 4 E4B)
CHRONO uses Gemma 4 E4B (4.5B) and the `google-genai` SDK to extract structured markers from heterogeneous lab report photographs and **audio dictations**. By performing this on-device, we ensure medical privacy while democratizing early detection for users who may only have access to paper records.

### Layer 2: Protocol-99 Agent (Gemma 4 26B)
When the Trident Signal identifies a co-moving anomaly (MCF > 0.61), the **Protocol-99 Agent** activates. Powered by Gemma 4 26B, this agent uses **Native Function Calling** and **Thinking Mode** (budget: 8192) to:
1. Validate the signal against confidence thresholds.
2. Investigate longitudinal trends.
3. Compute a Vascular Anomaly Score.
4. Generate a clinical-grade triage dossier and escalate to an oncologist.

## 4. Impact
In our demonstration scenario ("Priya"), CHRONO identifies a critical metabolic shift in **January 2024**. While her markers remained within population "normal" ranges, her personal velocity signaled a crisis. This led to the detection of a Stage 1 ovarian mass (93% 5-yr survival). Without CHRONO, her markers wouldn't have crossed population thresholds until 2026, by which time she would likely be Stage 3 (29% 5-yr survival).

## 5. Technology Track Target
- **Main Track:** Gemma 4 Good.
- **Unsloth Track:** Optimized 4-bit fine-tuning of Gemma 4 E4B for low-quality medical document OCR.
- **Agentic Track:** Protocol-99 ReAct triage workflow.

---
*CHRONO: Giving oncology the 3-year head start it needs.*
